NDC 3215-6522-01 - Buprenorphine and Naloxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 3215-6522
- Requested NDC
- 3215-6522-01
- Package NDCs from labels
- 3215-6522-01, 3215-6522-30
- Manufacturer
- Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC
- Effective date
- 2026-04-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine and Naloxone - Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | 2026-04-07 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 3215-6522-01 | Buprenorphine and Naloxone | 1 in 1 POUCH | FILM | 1 | 2 | |
| 3215-6522-30 | Buprenorphine and Naloxone | 30 in 1 CARTON | FILM | 30 | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Asclemed USA, Inc. | 7acf3bde-f858-4fbc-8a11-6741a3d27b8e | 2024-10-29 | Warnings | F850569PQR |
| Buprenorphine Sublingual C-III | BUPRENORPHINE SUBLINGUAL C-III | Direct_Rx | 22412030-a641-28d8-e063-6294a90a2fef | 2024-10-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine Sublingual C-III | BUPRENORPHINE SUBLINGUAL C-III | Direct_Rx | 248524c6-4c8b-a450-e063-6394a90a81ef | 2024-10-15 | Warnings, Adverse reactions | 56W8MW3EN1 |
| teruflex blood bag system with diversion blood sampling arm 70 ml cpda-1 | ANHYDROUS CITRIC ACID, TRISODIUM CITRATE DIHYDRATE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, DEXTROSE MONOHYDRATE, AND ADENINE | Terumo Corporation | 86b3a329-c83f-4977-92f5-0e9dfe1872d7 | 2024-10-10 | Warnings | XF417D3PSL |
| Bio Co-Enzyme Phase | CARDUUS MARIANUS, ASCORBICUM ACIDUM, CYSTEINUM, NATRUM OXALACETICUM, NICOTINAMIDUM, PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, THIAMINUM HYDROCHLORICUM, ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CERIUM OXALICUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, NADIDUM, NATRUM PYRUVICUM, PANTOTHENIC ACID, SUCCINICUM ACIDUM, ADRENALINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, HEPAR SULPHURIS CALCAREUM, SULPHUR, ACONITICUM ACIDUM, CIS-, | Deseret Biologicals, Inc. | afad858e-064f-454d-be78-da1501ffe853 | 2024-10-04 | Warnings | XF417D3PSL |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | Baxter Healthcare Corporation | 48137634-91d7-41e3-b54b-e4321d69668a | 2024-10-04 | Warnings, Adverse reactions | F850569PQR |
| TERUFLEX BLOOD with Diversion Blood Sampling Arm 70 mL CPDA-1 | ANHYDROUS CITRIC ACID, TRISODIUM CITRATE DIHYDRATE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, DEXTROSE MONOHYDRATE, AND ADENINE | Terumo Corporation | 39f2e11c-5a31-469f-b725-d096c1674421 | 2024-10-03 | Warnings | XF417D3PSL |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Bryant Ranch Prepack | ed549649-dcbd-41f7-a774-876906751c5a | 2024-10-03 | Warnings | F850569PQR |
| TERUFLEX Blood Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) for Collection of 450mL of Blood | ANHYDROUS CITRIC ACID, TRISODIUM CITRATE DIHYDRATE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, DEXTROSE MONOHYDRATE, AND ADENINE | Terumo Corporation | 02015040-9b71-4dbe-8f8d-e0d0951e8f93 | 2024-09-19 | Warnings | XF417D3PSL |
| Buprenorphine Sublingual | BUPRENORPHINE SUBLINGUAL | Direct_rx | 2204e135-6a0c-68a2-e063-6394a90ac019 | 2024-09-13 | Warnings, Adverse reactions | 56W8MW3EN1 |
| ammonia inhalants | INHALANT | Epic Medical Supply Corp | 20e849e5-8517-b9fd-e063-6394a90a0d23 | 2024-09-03 | Warnings | 5138Q19F1X |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | American Health Packaging | b05b0087-c0ef-40be-9bf3-3933f6cd3492 | 2024-08-20 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Quality Choice Effervescent Antacid and Pain Relief - Extra Strength | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | Chain Drug Marketing Association | 1f926637-a61c-8eb7-e063-6394a90a6502 | 2024-08-13 | Warnings | XF417D3PSL |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | American Health Packaging | 58fa9952-c8ab-4ebb-a073-15cc45f4832a | 2024-07-16 | Adverse reactions | 1Q73Q2JULR XF417D3PSL |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Eugia US LLC | c7fa8d4f-28a7-4ef5-aef8-cbd4328ce599 | 2024-07-06 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Eugia US LLC | 2725b9c0-5b1e-498b-9ec5-ee76a62e656a | 2024-07-06 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Advanced Rx of Tennessee, LLC | 1be2e38b-55ca-abea-e063-6394a90ac548 | 2024-06-27 | Warnings | F850569PQR |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID | Chartwell RX, LLC | 525136c9-7758-437b-b57b-94b905786825 | 2024-05-31 | Adverse reactions | 1Q73Q2JULR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | 19b0603b-241f-f439-e063-6294a90ae85f | 2024-05-30 | Warnings | F850569PQR |
| REFL HS | ADENOSINUM TRIPHOSPHORICUM DINATRUM, NADIDUM, ARGENTUM NITRICUM, IPECACUANHA, ROBINIA PSEUDOACACIA, SULPHUR, ORIGANUM VULGARE, DUODENUM (SUIS), ESOPHAGUS (SUIS), FUNICULUS UMBILICALIS SUIS, STOMACH (SUIS), NUX VOMICA, COUMARINUM, ERYTHRAEA CENTAURIUM, PANCREAS SUIS, MURIATICUM ACIDUM, CITRICUM ACIDUM, FORMICUM ACIDUM, SARCOLACTICUM ACIDUM, COENZYME A, PROTEUS (MORGANI) | Deseret Biologicals, Inc. | 83249aee-f58b-442d-9187-6de0cf070e4d | 2024-04-29 | Warnings | XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.